Render Target: SSR
Render Timestamp:
3/26/2025, 9:53:52 AM EDT
3/26/2025, 1:53:52 PM UTC
Commit: 8d93f7ebe45006d66c127727d817fc3f57c4fe9a
XML generation date: 2025-03-07 13:11:43.140
Product last modified at: 2024-05-30T07:04:27.173Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human Transforming Growth Factor β3 (hTGF-β3) #8425

We recommend the following alternatives

Human Transforming Growth Factor β3 (hTGF-β3): Image 1
The inhibition of IL-4 induced proliferation in HT-2 cells treated with increasing concentrations of hTGF-β3 was assessed. After 48 hour treatment with hTGF-β3, cells were incubated with a tetrazolium salt and the OD450-OD650 was determined.
This product is discontinued

Inquiry Info. # 8425

Please see our recommended alternatives.

Product Information

Product Usage Information

Reconstitution:

With carrier: Add sterile 20 mM Citrate, pH 3.0 to a final hTGF-β3 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.

Carrier free: Add sterile 20 mM Citrate, pH 3.0, or 20 mM Citrate, pH 3.0 containing protein to minimize absorption of hTGF-β3 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hTGF-β3 should be greater than 50 μg/ml.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM Citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-β3. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM Citrate, pH 3.0 containing 100 mM NaCl.

Storage

Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Product Description

MW (kDa) 12
Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β3. Less than 5% migrates as monomer hTGF-β3 under non-reduced (-) conditions. All lots are greater than 98% pure.
Endotoxin Less than 0.01 ng endotoxin/1 μg hTGF-β3.
Activity The bioactivity of recombinant hTGF-β3 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.02-0.1 ng/ml.
Molecular Formula Recombinant hTGF-β3 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,722. DTT-reduced protein migrates as a 12 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 22 kDa protein. The expected amino-terminal ALDTN of recombinant hTGF-β3 was verified by amino acid sequencing.

Source / Purification

Recombinant human TGF-β3 (hTGF-β3) Ala301-Ser412 (Accession #NP_003230) was expressed in human 293 cells at Cell Signaling Technology.

Background

TGF-β3 can induce cell proliferation and angiogenesis, and can promote some immune events while inhibiting others (1-3). TGF-β3 is produced by chondrocytes, glial cells, astrocytes and some cancer cells (3,4). TGF-β3 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,5). The oligomeric receptor complex phosphorylates subsets of SMAD proteins that then act to induce or suppress target genes (1,5). Based on knock-out studies in mice, TGF-β3 is critical for lung and palate development (6).

Pathways

Explore pathways related to this product.


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.